433701-34-9Relevant articles and documents
Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer
Lin, Shu-Yu,Chang Hsu, Yung,Peng, Yi-Hui,Ke, Yi-Yu,Lin, Wen-Hsing,Sun, Hsu-Yi,Shiao, Hui-Yi,Kuo, Fu-Ming,Chen, Pei-Yi,Lien, Tzu-Wen,Chen, Chun-Hwa,Chu, Chang-Ying,Wang, Sing-Yi,Yeh, Kai-Chia,Chen, Ching-Ping,Hsu, Tsu-An,Wu, Su-Ying,Yeh, Teng-Kuang,Chen, Chiung-Tong,Hsieh, Hsing-Pang
supporting information, p. 10108 - 10123 (2019/11/29)
Epidermal growth factor receptor (EGFR)-targeted therapy in non-small cell lung cancer represents a breakthrough in the field of precision medicine. Previously, we have identified a lead compound, furanopyrimidine 2, which contains a (S)-2-phenylglycinol
2-(3,4-dihydro-4-oxothieno[2,3-d]pyrimidin-2-ylthio) acetamides as a new class of falcipain-2 inhibitors. 3. design, synthesis and biological evaluation
Zhu, Jin,Chen, Tong,Liu, Jie,Ruoqun, Ma.,Lu, Weiqiang,Huang, Jin,Li, Honglin,Li, Jian,Jiang, Hualiang
experimental part, p. 785 - 797 (2009/05/27)
The cysteine protease falcipain-2 (FP-2) of Plasmodium falciparum is a principal cysteine protease and an essential hemoglobinase of erythrocytic P. falciparum trophozoites, making it become an attractive target enzyme for developing anti-malarial drugs.
THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF
-
Page/Page column 66-67, (2008/06/13)
Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are d
